Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Completed · Phase 2

Conditions studied: Kidney Cancer, Metastatic Cancer

In brief

This phase II trial is studying how well sorafenib works in treating patients with kidney cancer that has spread to the brain. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Key facts

Study ID

NCT00301847

Run by

National Cancer Institute (NCI)

People needed

44

Starts

2005-11-01

Last updated by the study team

2013-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Decatur Memorial Hospital Cancer Care Institute — Decatur, Illinois, United States
• Evanston Northwestern Health Care - Evanston Hospital — Evanston, Illinois, United States
• Ingalls Cancer Care Center at Ingalls Memorial Hospital — Harvey, Illinois, United States
• Cardinal Bernardin Cancer Center at Loyola University Medical Center — Maywood, Illinois, United States
• Oncology Hematology Associates of Central Illinois, PC - Peoria — Peoria, Illinois, United States
• Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
• Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana, United States
• CCOP - Northern Indiana CR Consortium — South Bend, Indiana, United States
• Oncology Care Associates, PLLC — Saint Joseph, Michigan, United States
• David C. Pratt Cancer Center at St. John's Mercy — St Louis, Missouri, United States
• Medical College of Wisconsin Cancer Center — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.